Format

Send to

Choose Destination
See comment in PubMed Commons below
J Vet Emerg Crit Care (San Antonio). 2009 Apr;19(2):158-64. doi: 10.1111/j.1476-4431.2009.00403.x.

Use of human immunoglobulin in addition to glucocorticoids for the initial treatment of dogs with immune-mediated hemolytic anemia.

Author information

1
Cummings School of Veterinary Medicine at Tufts University, North Grafton, MA 01536, USA.

Abstract

OBJECTIVE:

To determine the utility of human intravenous immunoglobulin (hIVIG) for the initial treatment of canine immune-mediated hemolytic anemia (IMHA).

DESIGN:

Blinded, randomized, clinical trial.

SETTING:

Veterinary teaching hospital.

ANIMALS:

Twenty-eight, client-owned dogs with primary IMHA.

INTERVENTIONS:

At enrollment, after diagnosis of IMHA, dogs were randomly assigned to receive either hIVIG or placebo, in a blinded fashion. For the next 14 days, all dogs received glucocorticoids as the sole immunosuppressant agent. All dogs received low-molecular-weight heparin as an anticoagulant. D-dimer concentrations were evaluated at the beginning and end of the study protocol to monitor for thromboembolic complications.

MEASUREMENTS AND MAIN RESULTS:

Twenty-five of 28 dogs (89%) were discharged from the hospital. Thirteen of those received hIVIG and 12 received placebo. Twenty-four dogs (86%) were alive 14 days after enrollment, and of these 13 received hIVIG and 11 received placebo. D-dimer concentrations were elevated in 86% of all dogs at the time of diagnosis.

CONCLUSIONS:

For initial treatment of dogs with IMHA, the addition of hIVIG to corticosteroid treatment did not improve initial response, nor did it shorten hospitalization.

[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center